Use of nonlinear mixed effect modeling for the intestinal absorption data: Application to ritonavir in the rat

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 61, Issue 1-2, 2005, Pages 20-26

  Munoz M J ^a   Merino Sanjuan M ^a   Lledo Garcia R ^a   Casabo V G ^a   Manez Castillejo F J ^a   Nacher A ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Anti HIV protease inhibitors; Bootstrap; Carrier mediated; Nonlinear mixed effects model (NONMEM); Ritonavir absorption; Ritonavir secretion

Indexed keywords

ANTIRETROVIRUS AGENT; DIMETHYL SULFOXIDE; DRUG CARRIER; PHENAZONE; RITONAVIR;

ANESTHESIA; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETERMINATION; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG MIXTURE; DRUG PENETRATION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; INTESTINE SECRETION; MALE; NONHUMAN; NONLINEAR SYSTEM; OBSERVATION; POPULATION; RAT; SMALL INTESTINE ABSORPTION;

ANIMALS; DIMETHYL SULFOXIDE; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MODELS, ANIMAL; NONLINEAR DYNAMICS; PERFUSION; RATS; RATS, WISTAR; RITONAVIR; SOLUBILITY;

EID: 23244461269     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2005.03.008     Document Type: Article

References (27)

1. J.W. Beach Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions Clin. Ther. 20 1 1998 2 25
2. C.L. Leen Perspectives on HAART: switch maintenance therapy Int. J. STD AIDS. 14 9 2003 577 582
3. R.M. Gulik, J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, D. McMahon, D.D. Richman, F.T. Valentine, L. Jonas, A. Meibohm, E.A. Emini, and J.A. Chodakewitz Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N. Engl. J. Med. 337 11 1997 734 739
4. D. Finzi, J. Blankson, and J.D. Siciliano Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV, even in patients on effective combination therapy Nat. Med. 5 1999 512 519
5. J.M. Kilby, A. Hill, and N. Buss The effect of ritonavir on saquinavir plasma concentrations is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects HIV Med. 3 2002 97 104
6. R.S. Cvetkovic, and K.L. Goa Lopinavir/Ritonavir: A review of its use in the management of HIV infection Drugs 63 8 2003 769 802
7. M.T. Huisman, J.W. Smit, K.M. Cormmentuyn, N. Zelcer, H.R. Wiltshire, J.H. Beijnen, and A.H. Schinkel AIDS 16 17 2002 2295 2301
8. N. Zelcer, M.T. Huisman, G. Reid, P. Wielinga, P. Breedveld, A. Kuil, P. Knipscheer, J.H. Schellens, A.H. Schinkel, and P. Borst Evidence for two interacting ligand binding sites in human multidrug protein 2 (ATP binding cassette C2) J. Biol. Chem. 278 26 2003 23538 23548
9. M.D. Perloff, L.L. Von Moltke, J.E. Marchand, and D.J. Greenblatt Ritonavir induces P-glycoprotein expression, multidrug resistance-associate protein (MRP1) expression and drug transporter-mediated activity in a human intestinal cell line J. Pharm. Sci. 90 11 2001 1829 1837
10. L. Huang, S.A. Wring, J.L. Woolley, K.R. Brouwer, C. Serabjit-Singh, and J.W. Polli Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors Drug Metab. Dispos. 29 5 2001 754 760
11. N. Shibata, W. Gao, H. Okamoto, T. Kishida, K. Iwasaki, Y. Yoshikawa, and K. Takada Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model J. Pharm. Sci. 91 3 2002 680 689
12. J.F. Lu, T.F. Blaschke, C. Flexner, S.L. Rosenkranz, and L.B. Sheiner AIDS Clinical Trials Group Protocol 378 Investigators, Model-Based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration Drug Metab. Dispos. 30 12 2002 1455 1461
13. J.T. Doluisio, N.F. Billups, L.W. Ditter, E.T. Sugita, and J.V. Swintosky Drugs absorption. I. an in situ rat gut technique yielding realistic absorption rates J. Pharm. Sci. 58 1969 1196 1199
14. M. Karlsson, and L. Sheiner Estimation of bioavailability when clearance varies with time Clin. Pharmacol. Ther. 55 1994 623 637
15. N. Ruiz-Balaguer, A. Nácher, V.G. Casabó, and M. Merino Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes Int. J. Pharm. 234 2002 101 111
16. A. Martín, J.M. Plá, J. Moreno, M.D. Pérez, J. Miralles, E. Collado, E. Sánchez, and A. Del Pozo Studies on the reliability of a bihyperbolic functional absorption model. I. Ring substituted anilines J. Pharmacokinet. Biopharm. 14 1986 615 633
17. M. Merino, J.E. Peris-Ribera, F. Torres-Molina, A. Sánchez- Picó, M.C. García-Carbonell, V.G. Casabó, A. Martín-Villodre, and J.M. Plá-Delfina Evidence of a specialized transport mechanism for the intestinal absorption of baclofen Biopharm. Drug Dispos. 10 1989 279 297
18. V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. McDowall, K.A. Pittman, and S. Spector Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies Pharm. Res. 9 1992 588 592
19. J.G. Wagner, Farmacocinética clínica. Ed. Reverté, Barcelona (1983).
20. J.T. Doluisio, W.G. Crouthamel, G.H. Tan, J.V. Swintosky, and L.W. Ditter Drug absorption. III. Effect of membrane storage on the kinetics of drug absorption J. Pharm. Sci. 59 1970 72 76
21. S.L. Beal, and L.B. Sheiner NONMEM User's Guides, NONMEM Project Group 1992 University of California San Francisco
22. P. Ruiz-Carreterro, M. Merino-Sanjuán, A. Nácher, and V.G. Casabó Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime Eur. J. Pharm. Sci. 21 2004 217 223
23. W.L. Chiou, and A. Barve Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats Pharm. Res. 15 1998 1792 1795
24. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
25. M. Sale, B.M. Sadler, and D.S. Stein Pharmacokinetic modelling and simulations of interaction of amprenavir and ritonavir Antimicrob. Agents Chemother. 46 3 2002 746 754
26. H. Gutmann, G. Fricker, J. Drewe, M. Toeroek, and D.S. Miller Interactions of HIV protease inhibitors with ATP dependent drug export proteins Mol. Pharmacol. 56 2 1999 383 389
27. E.I. Ette Stability and performance of a population pharmacokinetic model J. Clin. Pharmacol. 37 1997 486 495